Overview

ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure

Status:
Unknown status

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Collaborators:

Merck Sharp & Dohme Corp.
Toronto General Hospital
University Medical Center Groningen
University of Toronto

Treatments:

Ertugliflozin